Diabetes and fatty liver:Involvement of incretin and its benefit for fatty liver management  

作　　者：I Dewa Nyoman Wibawa I Ketut Mariadi Gde Somayana Cokorda Istri Yuliandari Krisnawardani Kumbara Dwijo Anargha Sindhughosa 

机构地区：[1]Department of Internal Medicine,Gastroentero-hepatology Division,Udayana University,Faculty of Medicine,Denpasar 80233,Bali,Indonesia [2]Internal Medicine Resident,Udayana University,Faculty of Medicine,Denpasar 80233,Bali,Indonesia

出　　处：《World Journal of Diabetes》2023年第5期549-559,共11页世界糖尿病杂志（英文版）（电子版）

摘　　要：Fatty liver disease is defined as liver condition characterized by hepatic steatosis,closely related to pathological conditions in type 2 diabetes and obesity.The high prevalence of fatty liver disease in obese patients with type 2 diabetes reached 70%,reflecting the importance of these conditions with fatty liver.Although the exact pathological mechanism of fatty liver disease,specifically non-alcoholic fatty liver disease(NAFLD)remains not completely revealed,insulin resistance is suggested as the major mechanism that bridged the development of NAFLD.Indeed,loss of the incretin effect leads to insulin resistance.Since incretin is closely related to insulin resistance and the resistance of insulin associated with the development of fatty liver disease,this pathway suggested a potential mechanism that explains the association between type 2 diabetes and NAFLD.Furthermore,recent studies indicated that NAFLD is associated with impaired glucagon-like peptide-1,resulting in decreased incretin effect.Nevertheless,improving the incretin effect becomes a reasonable approach to manage fatty liver disease.This review elucidates the involvement of incretin in fatty liver disease and recent studies of incretin as the management for fatty liver disease.

关 键 词：Fatty liver DIABETES INCRETIN Insulin resistance 

分 类 号：R587.1[医药卫生—内分泌] R575.5[医药卫生—内科学]